Rhenman & Partners Asset Management AB Buys Nektar Therapeutics Inc, Walgreens Boots Alliance Inc, Incyte Corp, Sells AbbVie Inc, Biogen Inc, Celgene Corp

• New Purchases: AET, LIVN, JNJ, DPLO, JHG, GOOGL,
• Added Positions: NKTR, WBA, INCY, SGMO, AGN, ONCE, LOXO, ALKS, CVS, SGEN,
• Reduced Positions: ABBV, BIIB, CELG, REGN, HZNP, ABMD, GKOS, ALXN, JAZZ, XNCR,
• Sold Out: ELGX, EPZM, NLNK, KERX, DERM, STAA, RARX,

For the details of Rhenman & Partners Asset Management AB's stock buys and sells, go to http://www.gurufocus.com/StockBuy.php?GuruName=Rhenman+%26+Partners+Asset+Management+AB

1. Nektar Therapeutics Inc (NKTR) - 617,652 shares, 3.09% of the total portfolio. Shares added by 197.72%
2. Horizon Pharma PLC (HZNP) - 1,632,212 shares, 2.77% of the total portfolio. Shares reduced by 18.68%
3. Vertex Pharmaceuticals Inc (VRTX) - 155,000 shares, 2.7% of the total portfolio. Shares added by 3.33%
4. Incyte Corp (INCY) - 383,763 shares, 2.63% of the total portfolio. Shares added by 141.42%
5. Abiomed Inc (ABMD) - 60,400 shares, 2.53% of the total portfolio. Shares reduced by 21.04%

Rhenman & Partners Asset Management AB initiated holding in Aetna Inc. The purchase prices were between $168.11 and $190.92, with an estimated average price of $178.27. The stock is now traded at around $189.26. The impact to a portfolio due to this purchase was 1.31%. The holding were 70,000 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB initiated holding in LivaNova PLC. The purchase prices were between $81.75 and $105.37, with an estimated average price of $90.73. The stock is now traded at around $104.77. The impact to a portfolio due to this purchase was 0.87%. The holding were 85,000 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB initiated holding in Johnson & Johnson. The purchase prices were between $119.4 and $131.76, with an estimated average price of $124.84. The stock is now traded at around $125.55. The impact to a portfolio due to this purchase was 0.75%. The holding were 60,000 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB initiated holding in Diplomat Pharmacy Inc. The purchase prices were between $19.19 and $28.13, with an estimated average price of $23.31. The stock is now traded at around $23.03. The impact to a portfolio due to this purchase was 0.37%. The holding were 142,364 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB initiated holding in Janus Henderson Group PLC. The purchase prices were between $30.39 and $34.21, with an estimated average price of $32.02. The stock is now traded at around $31.34. The impact to a portfolio due to this purchase was 0.04%. The holding were 11,828 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB initiated holding in Alphabet Inc. The purchase prices were between $1009.95 and $1184.07, with an estimated average price of $1087.78. The stock is now traded at around $1200.02. The impact to a portfolio due to this purchase was 0.02%. The holding were 178 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB added to a holding in Nektar Therapeutics Inc by 197.72%. The purchase prices were between $46.25 and $104.45, with an estimated average price of $76.82. The stock is now traded at around $48.67. The impact to a portfolio due to this purchase was 2.05%. The holding were 617,652 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB added to a holding in Walgreens Boots Alliance Inc by 340.00%. The purchase prices were between $59.7 and $68, with an estimated average price of $64.41. The stock is now traded at around $64.56. The impact to a portfolio due to this purchase was 1.57%. The holding were 330,000 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB added to a holding in Incyte Corp by 141.42%. The purchase prices were between $60.85 and $83.98, with an estimated average price of $68.39. The stock is now traded at around $69.49. The impact to a portfolio due to this purchase was 1.54%. The holding were 383,763 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB added to a holding in Sangamo Therapeutics Inc by 311.24%. The purchase prices were between $13.9 and $19.8, with an estimated average price of $16.61. The stock is now traded at around $15.07. The impact to a portfolio due to this purchase was 1.16%. The holding were 1,051,933 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB added to a holding in Allergan PLC by 108.41%. The purchase prices were between $143.8 and $175.19, with an estimated average price of $160.7. The stock is now traded at around $172.28. The impact to a portfolio due to this purchase was 1.11%. The holding were 125,045 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB added to a holding in Spark Therapeutics Inc by 162.72%. The purchase prices were between $62.06 and $90.59, with an estimated average price of $77.13. The stock is now traded at around $83.19. The impact to a portfolio due to this purchase was 0.93%. The holding were 177,600 shares as of 2018-06-30.

Rhenman & Partners Asset Management AB sold out a holding in Endologix Inc. The sale prices were between $4.07 and $6.63, with an estimated average price of $5.06.

Rhenman & Partners Asset Management AB sold out a holding in Epizyme Inc. The sale prices were between $12.85 and $18.45, with an estimated average price of $15.53.

Rhenman & Partners Asset Management AB sold out a holding in NewLink Genetics Corp. The sale prices were between $3.86 and $7.32, with an estimated average price of $5.09.

Rhenman & Partners Asset Management AB sold out a holding in Keryx Biopharmaceuticals Inc. The sale prices were between $3.63 and $5.82, with an estimated average price of $4.86.

Rhenman & Partners Asset Management AB sold out a holding in Dermira Inc. The sale prices were between $7.12 and $11.62, with an estimated average price of $9.33.

Rhenman & Partners Asset Management AB sold out a holding in Staar Surgical Co. The sale prices were between $13.95 and $32.65, with an estimated average price of $23.3.